Novo Nordisk
NVO
#21
Rank
โ‚ฌ434.82 B
Marketcap
100,05ย โ‚ฌ
Share price
2.57%
Change (1 day)
5.72%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Revenue for Novo Nordisk (NVO)

Revenue in 2024 (TTM): โ‚ฌ34.58 Billion

According to Novo Nordisk's latest financial reports the company's current revenue (TTM ) is โ‚ฌ35.47 Billion. In 2023 the company made a revenue of โ‚ฌ30.58 Billion an increase over the revenue in the year 2022 that were of โ‚ฌ23.35 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Novo Nordisk from 1996 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚ฌ34.58 B13.05%
2023 โ‚ฌ30.58 B30.98%
2022 โ‚ฌ23.35 B20.16%
2021 โ‚ฌ19.43 B21.21%
2020 โ‚ฌ16.03 B-1.71%
2019 โ‚ฌ16.31 B5.91%
2018 โ‚ฌ15.40 B7.26%
2017 โ‚ฌ14.35 B-8.89%
2016 โ‚ฌ15.76 B7.73%
2015 โ‚ฌ14.63 B14.68%
2014 โ‚ฌ12.75 B18.3%
2013 โ‚ฌ10.78 B4.68%
2012 โ‚ฌ10.30 B9.17%
2011 โ‚ฌ9.43 B16.91%
2010 โ‚ฌ8.07 B19.78%
2009 โ‚ฌ6.73 B3.46%
2008 โ‚ฌ6.51 B21.02%
2007 โ‚ฌ5.38 B7.28%
2006 โ‚ฌ5.01 B7.84%
2005 โ‚ฌ4.65 B27.59%
2004 โ‚ฌ3.64 B8.67%
2003 โ‚ฌ3.35 B-0.12%
2002 โ‚ฌ3.35 B-14.89%
2001 โ‚ฌ3.94 B-12.5%
2000 โ‚ฌ4.51 B50.06%
1999 โ‚ฌ3.00 B32.89%
1998 โ‚ฌ2.26 B11.43%
1997 โ‚ฌ2.03 B13.11%
1996 โ‚ฌ1.79 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚ฌ52.88 B 49.05%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ38.83 B 9.47%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ45.08 B 27.07%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ50.85 B 43.34%๐Ÿ‡ซ๐Ÿ‡ท France